Business
Movano Health's Proprietary Cuffless Blood Pressure Device Once Again Achieves Accuracy Commensurate with the FDA's Requirements
Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced positive results of its most recent 81-participant blood pressure clinical study. Movano Health's prototype demonstrated a level of accuracy well within the standards recognized by the FDA for blood pressure monitoring devices, achieving an overall mean absolute difference (MAD) of 4.9 mmHg, which significantly exceeds the 7 mmHg MAD threshold required per a standard for wearable, cuffless blood pressure measuring devi
About this update from Corvex, Inc.
[{"type":"text","content":"Leveraging the Company's System-on-a-Chip (SoC), the clinical study results are another significant step forward in commercializing a cuffless, radio frequency (RF)-enabled blood pressure device","length":198,"tagName":"p","attribs":{}},{"type":"text","content":"PLEASANTON, Calif., April 22, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced positive results of its most recent 81-participant blood pressure clinical study. Movano Health's prototype demonstrated a level of accuracy well within the standards recognized by the FDA for blood pressure monitoring devices, achieving an overall mean absolute difference (MAD) of 4.9 mmHg, which significantly exceeds the 7 mmHg MAD threshold required per a standard for wearable, cuffless blood pressure measuring devices (IEEE1708a-2019).","length":591,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Movano)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Movano)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":87,"url":"https://media.zenfs.com/en/prnewswire.com/ef6fdff10fc2b7e2a95dba489ac989a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/buztdzCn0bbCDZSewjXxeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/ef6fdff10fc2b7e2a95dba489ac989a8","width":400,"height":87}},"href":"https://mma.prnewswire.com/media/1984306/Movano_evie_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Hypertension has reached epidemic proportions in the United States and is often labeled the silent killer as many don't know they are affected. According to the American Heart Association, high blood pressure affects half of Americans ages 20 years and older – or more than 122 million people – and 59 million Americans have prehypertension, making longitudinal blood pressure monitoring arguably the next frontier in continuous monitoring and the single most important clinical metric. Movano Health's cutting-edge RF technology has the potential to empower individuals and their clinicians to better monitor and manage high blood pressure on a daily basis.","length":676,"tagName":"p"},{"type":"text","content":"This most recent study incorporated the latest version of the Company's wrist-worn wearable proto...